- Impact of the Number of Infusions on 2-Year Results of Islet-After-Kidney Transplantation in the GRAGIL Network
[作者：Borot, S; Niclauss, N; Wojtusciszyn, A; Brault, C; Demuylder-Mischler, S; Muller, Y; Giovannoni, L; Parnaud, G; Meier, R; Badet, L; Bayle, F; Frimat, L; Kessler, L; Morelon, E; Penfornis, A; Thivolet, C; Toso, C; Morel, P; Bosco, D; Colin, C; Benhamou, PY; Berney, T,期刊：Transplantation, 页码：1031-1038 , 文章类型： Article，,卷期：2011年92-9]
- Background. Insulin independence after islet transplantation is generally achieved after multiple infusions. However, single infusion would increase the number of recipients. Our aim was to evaluate the results of islet-...
- Thymoglobulin Versus Basiliximab Induction Therapy for Simultaneous Kidney-Pancreas Transplantation: Impact on Rejection, Graft Function, and Long-Term Outcome
[作者：Bazerbachi, F; Selzner, M; Boehnert, MU; Marquez, MA; Norgate, A; McGilvray, ID; Schiff, J; Cattral, MS,期刊：Transplantation, 页码：1039-1043 , 文章类型： Article，,卷期：2011年92-9]
- Background. Thymoglobulin (ATG) and basiliximab induction therapies are used by the majority of centers for pancreas transplantation today. Although both strategies have different mechanisms, there is a paucity of studie...
- Epidemiology of Cytomegalovirus Infection After Pancreas Transplantation
[作者：Parsaik, AK; Bhalla, T; Dong, M; Rostambeigi, N; Dierkhising, RA; Dean, P; Abraham, R; Prieto, M; Kremers, WK; Razonable, RR; Kudva, YC,期刊：Transplantation, 页码：1044-1050 , 文章类型： Article，,卷期：2011年92-9]
- Background. Epidemiology of cytomegalovirus (CMV) infection has not been comprehensively studied after all three types of pancreas transplant (PT) including simultaneous pancreas-kidney transplantation (SPK), pancreas tr...
- Direct Renin Inhibition in a Rat Model of Chronic Allograft Injury
[作者：Rusai, K; Schmaderer, C; Hermans, JJR; Lutz, J; Heemann, U; Baumann, M,期刊：Transplantation, 页码：999-1004 , 文章类型： Article，,卷期：2011年92-9]
- Background. Blockade of the renin-angiotensin system (RAS) with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II (Ang II) receptor blockers (ARBs) slow the progression of various chronic kidney diseases a...
|